Sun Pharmaceutical Industries has secured approval from the US Food and Drug Administration for an updated label of UNLOXCYT, incorporating long-term efficacy data for Cutaneous Squamous Cell Carcinoma treatment.

Sun Pharmaceutical Industries has secured approval from the US Food and Drug Administration for an updated label of UNLOXCYT, incorporating long-term efficacy data for Cutaneous Squamous Cell Carcinoma treatment.

Sun Pharmaceutical Industries Ltd. has received approval from the US Food and Drug Administration (USFDA) for an updated label for its medication UNLOXCYT (tretinoin), which is used to treat a rare skin condition called Cutaneous Squamous Cell Carcinoma (CSCC) in...